Fiche société
Uma Borate
Traitements, essais et publications liés.
Traitements7programmes
Essais4liés
Publications18liées
SourceDBlocale
Traitements
7| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Bone Marrow AspirationThis phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to treat. Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a class of medications called anthracyclines. It also works by slowing or stopping the growth of cancer cells in the body. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment regimens may work better in getting rid of more AML compared to the standard approach of cytarabine and daunorubicin. | Cancer, SEP | Phase 2 | À vérifier | United States | À vérifier |
| Bone marrow biopsySelinexor has shown single-agent activity in a current phase I study enrolling patients with relapsed/refractory AML with durable complete remissions (CR), complete remissions with incomplete hematologic recovery (CRi), partial remissions (PR), and stable disease (SD) observed. Furthermore, common toxicities included nausea, fatigue, and anorexia and were manageable with supportive care agents. Additionally, CLAG chemotherapy has proven activity in relapsed and refractory AML, and has been shown to be a relatively well tolerated regimen without significant non-hematologic toxicity. Given the established role of CLAG chemotherapy, the single agent activity of selinexor, and their non-overlapping toxicities, the investigators propose a phase I/II open label study of selinexor in combination with CLAG for the treatment of patients with relapsed/refractory AML. | Cancer, SEP | Phase 2 | Traitement symptomatique | United States | À vérifier |
| CytarabineSelinexor has shown single-agent activity in a current phase I study enrolling patients with relapsed/refractory AML with durable complete remissions (CR), complete remissions with incomplete hematologic recovery (CRi), partial remissions (PR), and stable disease (SD) observed. Furthermore, common toxicities included nausea, fatigue, and anorexia and were manageable with supportive care agents. Additionally, CLAG chemotherapy has proven activity in relapsed and refractory AML, and has been shown to be a relatively well tolerated regimen without significant non-hematologic toxicity. Given the established role of CLAG chemotherapy, the single agent activity of selinexor, and their non-overlapping toxicities, the investigators propose a phase I/II open label study of selinexor in combination with CLAG for the treatment of patients with relapsed/refractory AML. | Cancer, Myasthénie, SEP | Phase 2 | Traitement symptomatique | United States | À vérifier |
| hydroxyureaThis phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus (HPV)-related oropharyngeal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, hydroxyurea, fluorouracil, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving nab-paclitaxel and carboplatin before chemoradiation may make the tumor smaller and reduce the amount of chemotherapy and radiation therapy needed. Assigning chemotherapy and radiation therapy based on response (response-based therapy) and giving patients who are responding well lower doses of treatment may help reduce the occurrence of side effects. | Cancer | Phase 2 | À vérifier | United States | À vérifier |
| CytarabineSelinexor has shown single-agent activity in a current phase I study enrolling patients with relapsed/refractory AML with durable complete remissions (CR), complete remissions with incomplete hematologic recovery (CRi), partial remissions (PR), and stable disease (SD) observed. Furthermore, common toxicities included nausea, fatigue, and anorexia and were manageable with supportive care agents. Additionally, CLAG chemotherapy has proven activity in relapsed and refractory AML, and has been shown to be a relatively well tolerated regimen without significant non-hematologic toxicity. Given the established role of CLAG chemotherapy, the single agent activity of selinexor, and their non-overlapping toxicities, the investigators propose a phase I/II open label study of selinexor in combination with CLAG for the treatment of patients with relapsed/refractory AML. | Cancer | Phase 1/2 | Traitement symptomatique | United States | À vérifier |
| CytarabineSelinexor has shown single-agent activity in a current phase I study enrolling patients with relapsed/refractory AML with durable complete remissions (CR), complete remissions with incomplete hematologic recovery (CRi), partial remissions (PR), and stable disease (SD) observed. Furthermore, common toxicities included nausea, fatigue, and anorexia and were manageable with supportive care agents. Additionally, CLAG chemotherapy has proven activity in relapsed and refractory AML, and has been shown to be a relatively well tolerated regimen without significant non-hematologic toxicity. Given the established role of CLAG chemotherapy, the single agent activity of selinexor, and their non-overlapping toxicities, the investigators propose a phase I/II open label study of selinexor in combination with CLAG for the treatment of patients with relapsed/refractory AML. | Cancer | Phase 1/2 | Traitement symptomatique | United States | À vérifier |
| Bone marrow biopsySelinexor has shown single-agent activity in a current phase I study enrolling patients with relapsed/refractory AML with durable complete remissions (CR), complete remissions with incomplete hematologic recovery (CRi), partial remissions (PR), and stable disease (SD) observed. Furthermore, common toxicities included nausea, fatigue, and anorexia and were manageable with supportive care agents. Additionally, CLAG chemotherapy has proven activity in relapsed and refractory AML, and has been shown to be a relatively well tolerated regimen without significant non-hematologic toxicity. Given the established role of CLAG chemotherapy, the single agent activity of selinexor, and their non-overlapping toxicities, the investigators propose a phase I/II open label study of selinexor in combination with CLAG for the treatment of patients with relapsed/refractory AML. | Cancer | Phase 1/2 | Traitement symptomatique | United States | À vérifier |
Essais cliniques
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Biospecimen Collection | Cancer | Phase 2 | NCT06930352 | Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy | RECRUITING |
| Bone marrow biopsy | Cancer | Phase 1/2 | NCT05455697 | Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING |
| Cytarabine | Cancer | Phase 1/2 | NCT03214562 | Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | RECRUITING |
| Cytarabine | Cancer | Phase 1/2 | NCT07053020 | A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) | NOT_YET_RECRUITING |
Publications
18| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Bone marrow biopsy | Extensive bilateral pulmonary embolism revealing iron deficiency-masked JAK2-positive polycythemia vera: A case report. | Radiology case reports | ||
| Bone marrow biopsy | Bone marrow predominant presentation of EGFR mutated NSCLC: Report of two cases. | Radiology case reports | ||
| Bone marrow biopsy | Unique presentation of immune thrombocytopenic purpura in adult osteopetrosis: A case report. | Radiology case reports | ||
| Cytarabine | BMP and ERK signaling modulate AML-stroma interactions and contextually alter cytarabine sensitivity in AML cells. | Life sciences | ||
| Cytarabine | NAT10 drives chemoresistance in AML through ac4C-dependent stabilization of PLEKHA4. | Biochemical pharmacology | ||
| hydroxyurea | Thrombotic burden and longitudinal outcomes in Thai patients with polycythemia vera. | Annals of medicine | ||
| hydroxyurea | Tubular dysfunction in stable adult sickle cell patients in Kinshasa: prevalence and associated factors - a cross-sectional study. | Renal failure | ||
| hydroxyurea | Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study. | Hematology (Amsterdam, Netherlands) | ||
| hydroxyurea | Evaluation of The Use of Hydroxyurea in Treating Children With Sickle Cell Anemia in Central Africa's Rural Area. | EJHaem | ||
| hydroxyurea | Mechanisms of Hydroxyurea-Mediated DNA Damage Potentiation in Fanconi Anemia Cells. | International journal of molecular sciences | ||
| hydroxyurea | Cross-study analyses of the ropeginterferon alfa-2b effect on phlebotomy in low- and high-risk patients with polycythemia vera. | Leukemia & lymphoma | ||
| hydroxyurea | Hepatobiliary Abnormalities in Children With Sickle Cell Anemia Attending a Tertiary Hospital in Northwestern Tanzania. | Journal of pediatric hematology/oncology | ||
| hydroxyurea | Feasibility and Safety of Venetoclax for Cytoreduction During Induction Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. | European journal of haematology | ||
| hydroxyurea | Treating a patient with ADP porphyria through suppression of both hepatic and erythroid ALA production. | Orphanet journal of rare diseases | ||
| hydroxyurea | S-phase targeted treatment triggers caspase-dependent lytic immunogenic cell death with pyroptotic features in cancers. | Cell death and differentiation | ||
| hydroxyurea | Cancer history and second cancer risk in polycythemia vera and essential thrombocythemia. | Blood cancer journal | ||
| hydroxyurea | Enigmatic Case of Adult-Onset Langerhans Cell Histiocytosis with Aggressive Bony Involvement. | Journal of Brown hospital medicine | ||
| hydroxyurea | Hydroxyurea Promotes Brain Development in Children with Sickle Cell Anemia. | Brain research bulletin |